nilotinib tartrate · Azurity · NDA 219293
Danziten
Earliest generic entry, as listed · earliest of 2 marketed strengths
18 Feb 2040
Blocked by patent: US 10874671, US 11793809, US 12403140, US 12629369.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10874671 | drug product · sets the listed date | 18 Feb 2040 |
| US 11793809 | drug product · sets the listed date | 18 Feb 2040 |
| US 12403140 | drug product · sets the listed date | 18 Feb 2040 |
| US 12629369 | drug product · sets the listed date | 18 Feb 2040 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219293 · 001 · RLD | tablet, oral | EQ 71MG BASE | 18 Feb 2040 |
| 219293 · 002 · RLD | tablet, oral | EQ 95MG BASE | 18 Feb 2040 |